1-tetralone-6-acetic acid | 125564-40-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-tetralone-6-acetic acid
• 英文别名: 1-oxo-3,4,-dihydro-(2H)-naphth-6-yl acetic acid；(1-tetralon-6-yl)acetic acid；6-Carboxymethyltetralone；2-(5-oxo-7,8-dihydro-6H-naphthalen-2-yl)acetic acid
• CAS: 125564-40-1
• 化学式: C₁₂H₁₂O₃
• 分子量: 204.225
• InChiKey: DRNNZMMOBSRGPG-UHFFFAOYSA-N

物化性质

• 沸点：
  409.6±24.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  草酰氯 、 1-tetralone-6-acetic acid 以 氯仿 为溶剂， 生成 1-[1-oxo-3,4,-dihydro-(2H)-naphth-6-yl]acetyl-2-(pyrrolidin-1-yl)methyl-piperidine hydrochloride
  参考文献：
  名称：

  Azacyclic compounds and their use as analgesic agents

  摘要：

  化合物或其溶剂化物或盐的化学式（I）##STR1##其中：R.sub.1和R.sub.2独立地为氢、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.3-6环烷基或C.sub.4-12环烷基烷基，或者一起形成C.sub.2-8分支或线性聚亚甲基或C.sub.2-6烯基烯基，可选择地被杂原子取代，前提是R.sub.1和R.sub.2不能同时为氢；R.sub.3为氢、C.sub.1-6烷基，优选甲基或乙基，苯基，或者R.sub.3和R.sub.1一起形成--（CH.sub.2）.sub.3--或--（CH.sub.2）.sub.4--基团；p为1、2、3或4，R为化学式（II）##STR2##其中，--（CHR.sub.4）.sub.n--X--基团在与YR.sub.5或R.sub.6的间位或对位上，R.sub.4为氢或C.sub.1-6烷基，优选为氢；n为0、1或2，优选为1；X为直接键，或O、S或NR.sub.a，其中R.sub.a为氢或C.sub.1-6烷基，优选为直接键；Y为>C.dbd.O、>CHOH、--S.dbd.O或--SO.sub.2；每个R.sub.5和R.sub.6为C.sub.1-6烷基，或者R.sub.5和R.sub.6连接在一起，R.sub.5代表--（Z）.sub.m--，其中m为0或1，Z为O、S或NR.sub.7，R.sub.7为氢或C.sub.1-6烷基，R.sub.6代表--（CH.sub.2）.sub.9--，其中q为1到4的整数，优选为2或3，并且其中一个或多个--（CH.sub.2）--基团可选择地被C.sub.1-6烷基取代，用于治疗疼痛。

  公开号：

  US04994450A1
• 作为产物：
  描述：

  N-(5-氧代-5,6,7,8-四氢萘酚-2-基)乙酰胺 在 硫酸 、 氢溴酸 、 sodium hydride 、 copper(I) bromide 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 13.0h， 生成 1-tetralone-6-acetic acid
  参考文献：
  名称：

  Selective .kappa.-Opioid Agonists: Synthesis and Structure-Activity Relationships of Piperidines Incorporating an Oxo-Containing Acyl Group

  摘要：

  This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2-(aminomethyl)piperidine derivatives, using K-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their kappa-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]-1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED(50)s of 0.47 and 0.73 mu mol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective K-agonists, has a reduced propensity to cause a number of K-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED(50) Of 26.5 mu mol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.

  DOI：

  10.1021/jm00047a006

文献信息

• Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
  申请人：Pharmacia Corporation

  公开号：US20040127492A1

  公开（公告）日：2004-07-01

  Cyclic pyrazole compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2 in a subject in need of such inhibition, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本发明涉及一种环状吡唑化合物，其能够抑制丝裂原活化蛋白激酶激活蛋白激酶-2（MK-2）。本发明还描述了制备这种化合物的方法，以及一种使用它们来抑制需要这种抑制的受体的方法，其中该方法涉及向受体中注射本发明的MK-2抑制化合物。本发明还描述了包含本MK-2抑制化合物的药物组合物和工具箱。
• Azacyclic compounds, processes for their preparation and their pharmaceutical use
  申请人：Dr. Lo. Zambeletti S.p.A.

  公开号：EP0333315B1

  公开（公告）日：1991-06-12
• NOVEL 1-(2H-1-OXO-3,4-DIHYDRONAPHTYL-6)-ACETYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE
  申请人：Dr. Lo. Zambeletti S.p.A.

  公开号：EP0594611A1

  公开（公告）日：1994-05-04
• PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS
  申请人：PFIZER INC.

  公开号：EP0817772B1

  公开（公告）日：2003-01-29
• US4994450A
  申请人：——

  公开号：US4994450A

  公开（公告）日：1991-02-19